Using a syngeneic immunocompetent subcutaneous tumor model, ICT efficacy was compared in wild-type C57BL/6 (WT) and age-matched syngeneic MPO-deficient (MPO−/−) animals using the KPCY6419 murine PDAC cell line [26]. The gene discussed is MPO; the disease is neoplasm.